Glycodendrimers as Potential Multitalented Therapeutics in Alzheimer’s Disease

Forskningsoutput: Kapitel i bok/rapport/Conference proceedingKapitel samlingsverk

Standard

Glycodendrimers as Potential Multitalented Therapeutics in Alzheimer’s Disease. / Klementieva, Oxana.

Dendrimers, Dendrons and Dendritic Polymers. red. / Barbara Ziemba; Ida Franiak-Pietryga; Dzmitry Shcharbin. Vol. Dendrimers, Dendrons and Dendritic Polymers London, United Kingdom : InTech Open Access Publisher, 2019. s. 1-16.

Forskningsoutput: Kapitel i bok/rapport/Conference proceedingKapitel samlingsverk

Harvard

Klementieva, O 2019, Glycodendrimers as Potential Multitalented Therapeutics in Alzheimer’s Disease. i B Ziemba, I Franiak-Pietryga & D Shcharbin (red), Dendrimers, Dendrons and Dendritic Polymers. vol. Dendrimers, Dendrons and Dendritic Polymers, InTech Open Access Publisher, London, United Kingdom, s. 1-16. https://doi.org/10.5772/intechopen.88974

APA

Klementieva, O. (2019). Glycodendrimers as Potential Multitalented Therapeutics in Alzheimer’s Disease. I B. Ziemba, I. Franiak-Pietryga, & D. Shcharbin (Red.), Dendrimers, Dendrons and Dendritic Polymers (Vol. Dendrimers, Dendrons and Dendritic Polymers, s. 1-16). London, United Kingdom: InTech Open Access Publisher. https://doi.org/10.5772/intechopen.88974

CBE

Klementieva O. 2019. Glycodendrimers as Potential Multitalented Therapeutics in Alzheimer’s Disease. Ziemba B, Franiak-Pietryga I, Shcharbin D, redaktörer. I Dendrimers, Dendrons and Dendritic Polymers. London, United Kingdom: InTech Open Access Publisher. s. 1-16. https://doi.org/10.5772/intechopen.88974

MLA

Klementieva, Oxana "Glycodendrimers as Potential Multitalented Therapeutics in Alzheimer’s Disease"., Ziemba, Barbara Franiak-Pietryga, Ida Shcharbin, Dzmitry (redaktörer). Dendrimers, Dendrons and Dendritic Polymers. London, United Kingdom: InTech Open Access Publisher. 2019, 1-16. https://doi.org/10.5772/intechopen.88974

Vancouver

Klementieva O. Glycodendrimers as Potential Multitalented Therapeutics in Alzheimer’s Disease. I Ziemba B, Franiak-Pietryga I, Shcharbin D, redaktörer, Dendrimers, Dendrons and Dendritic Polymers. Vol. Dendrimers, Dendrons and Dendritic Polymers. London, United Kingdom: InTech Open Access Publisher. 2019. s. 1-16 https://doi.org/10.5772/intechopen.88974

Author

Klementieva, Oxana. / Glycodendrimers as Potential Multitalented Therapeutics in Alzheimer’s Disease. Dendrimers, Dendrons and Dendritic Polymers. redaktör / Barbara Ziemba ; Ida Franiak-Pietryga ; Dzmitry Shcharbin. Vol. Dendrimers, Dendrons and Dendritic Polymers London, United Kingdom : InTech Open Access Publisher, 2019. s. 1-16

RIS

TY - CHAP

T1 - Glycodendrimers as Potential Multitalented Therapeutics in Alzheimer’s Disease

AU - Klementieva, Oxana

PY - 2019/9/9

Y1 - 2019/9/9

N2 - Finding successful therapies for the treatment of Alzheimer’s disease (AD) is one of the most challenging tasks existing for human health. Several drugs have been found and validated in preclinical studies with some success, but not with the desired breakthroughs in the following clinical development phases. AD causes multiple brain dysfunctions that can be described as a brain organ failure, resulting in significant cognitive decline. Aggregation of amyloid proteins and neuronal loss are the hallmarks of AD. Thus, one of the strategies to treat AD is to find a multifunctional drug that may combine both anti-aggregation and neuroprotective properties. Such a candidate could be chemically modified dendrimers. Dendrimers are branched, nonlinear molecules with multiple reactive groups located on their surface. Chemical modification of reactive surface groups defines the property of the dendrimers. In this chapter, I will discuss poly(propylene imine) dendrimers with the surface functionalized with histidine and maltose as an example of a multifunctional therapeutic drug candidate able to protect the memory of AD transgenic model mice.

AB - Finding successful therapies for the treatment of Alzheimer’s disease (AD) is one of the most challenging tasks existing for human health. Several drugs have been found and validated in preclinical studies with some success, but not with the desired breakthroughs in the following clinical development phases. AD causes multiple brain dysfunctions that can be described as a brain organ failure, resulting in significant cognitive decline. Aggregation of amyloid proteins and neuronal loss are the hallmarks of AD. Thus, one of the strategies to treat AD is to find a multifunctional drug that may combine both anti-aggregation and neuroprotective properties. Such a candidate could be chemically modified dendrimers. Dendrimers are branched, nonlinear molecules with multiple reactive groups located on their surface. Chemical modification of reactive surface groups defines the property of the dendrimers. In this chapter, I will discuss poly(propylene imine) dendrimers with the surface functionalized with histidine and maltose as an example of a multifunctional therapeutic drug candidate able to protect the memory of AD transgenic model mice.

KW - dendrimer, histidine, aggregation, synapse, memory, Alzheimer’s disease

U2 - 10.5772/intechopen.88974

DO - 10.5772/intechopen.88974

M3 - Book chapter

VL - Dendrimers, Dendrons and Dendritic Polymers

SP - 1

EP - 16

BT - Dendrimers, Dendrons and Dendritic Polymers

A2 - Ziemba, Barbara

A2 - Franiak-Pietryga, Ida

A2 - Shcharbin, Dzmitry

PB - InTech Open Access Publisher

CY - London, United Kingdom

ER -